FLT3 and acute myeloid leukemia: A novel NGS-based MRD assay detecting FLT3-ITD showed that reduction in mutation burden after treatment with gilteritinib, a FLT3 inhibitor, in patients with relapsed or refractory AML (NCT02014558) was linked to longer median overall survival (87).